The New York venture firm calls itself a team of "lateralists." Behind the language is a practical model: lead early, cross categories and stay close as founders turn technical possibility into a company people want.
Deborah Jackson left Wall Street to fund the founders it kept overlooking. A decade later, Plum Alley has put $100M-plus into CRISPR, wastewater sensors and autonomous freight - and turned its members into the people writing the checks.
A female-founded merchant bank in Singapore is quietly wiring together capital, regulators and non-dilutive grants to push quantum, climate and brain-health science out of the lab - and it is measuring the results in billions mobilized, not just term sheets signed.